Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various vet… Read more
Wuhan Hvsen Biotechnology Co Ltd (300871) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.028x
Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has a cash flow conversion efficiency ratio of 0.028x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.06 Million) by net assets (CN¥2.12 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wuhan Hvsen Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Wuhan Hvsen Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dong Yi Ri Sheng Home Decoration Group Co Ltd
SHE:002713
|
0.017x |
|
Metall Zug AG
PINK:MTLZF
|
-0.012x |
|
Elopak ASA
PINK:ELPKF
|
0.180x |
|
GlobalData Plc
PINK:GLDAF
|
0.023x |
|
Shanghai Join Buy Co Ltd
SHG:600838
|
0.003x |
|
Xinjiang Talimu Agriculture Development Co Ltd
SHG:600359
|
-0.010x |
|
Schweitzer-Mauduit International Inc
F:MH2
|
0.183x |
|
Hengbo Holdings Co. Ltd. A
SHE:301225
|
N/A |
Annual Cash Flow Conversion Efficiency for Wuhan Hvsen Biotechnology Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.47 Billion | CN¥43.53 Million | 0.030x | -51.74% |
| 2023-12-31 | CN¥1.51 Billion | CN¥92.92 Million | 0.062x | -1.84% |
| 2022-12-31 | CN¥1.54 Billion | CN¥96.68 Million | 0.063x | -34.79% |
| 2021-12-31 | CN¥1.62 Billion | CN¥155.72 Million | 0.096x | +174.38% |
| 2020-12-31 | CN¥1.38 Billion | CN¥48.35 Million | 0.035x | -87.40% |
| 2019-12-31 | CN¥378.28 Million | CN¥105.24 Million | 0.278x | +327.97% |
| 2018-12-31 | CN¥324.52 Million | CN¥21.10 Million | 0.065x | -82.00% |
| 2017-12-31 | CN¥223.11 Million | CN¥80.56 Million | 0.361x | -6.91% |
| 2016-12-31 | CN¥154.70 Million | CN¥60.00 Million | 0.388x | -- |